Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
暂无分享,去创建一个
Elizabeth Stewart | P. Grohar | P. Houghton | K. Janeway | A. LeBlanc | R. Gorlick | S. Borinstein | F. Navid | R. Majzner | A. Huang | M. Isakoff | M. Bishop | E. Slotkin | Ryan D. Roberts | P. Hingorani | C. London | Emily G Greengard | Katharine Offer | Damon R Reed | Sarah B Whittle | E. Alejandro Sweet Cordero | Michael S. Isakoff
[1] S. Seaman,et al. The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models , 2021, Clinical Cancer Research.
[2] C. Mazcko,et al. Improving human cancer therapy through the evaluation of pet dogs , 2020, Nature reviews. Cancer.
[3] B. Teicher,et al. Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium , 2020, Pediatric blood & cancer.
[4] D. Reed,et al. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma , 2020, International journal of cancer.
[5] Jianguo Xu,et al. CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.
[6] H. Wang,et al. Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma , 2020, Cancer & Metabolism.
[7] P. A. Futreal,et al. Immuno-genomic landscape of osteosarcoma , 2020, Nature Communications.
[8] J. Blay,et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.
[9] P. Meltzer,et al. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group , 2019, Cancer.
[10] P. Houghton,et al. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force , 2019, F1000Research.
[11] M. Sydes,et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.
[12] A. Shelat,et al. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. , 2019, Cancer letters.
[13] P. Sorensen,et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors , 2019, Clinical Cancer Research.
[14] S. Sasagawa,et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo , 2019, Oncotarget.
[15] J. Yustein,et al. Generation of patient‐derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas , 2018, Pediatric blood & cancer.
[16] R. Goldsby,et al. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group , 2018, Pediatric blood & cancer.
[17] Marcus R. Breese,et al. Genome-Informed Targeted Therapy for Osteosarcoma. , 2018, Cancer discovery.
[18] C. Boese,et al. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma , 2018, Oncotarget.
[19] L. Wagner,et al. Immunotherapy for osteosarcoma: Where do we go from here? , 2018, Pediatric blood & cancer.
[20] B. Morland,et al. Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). , 2018 .
[21] W. London,et al. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma , 2018, Pediatric blood & cancer.
[22] B. Vincenzi,et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment , 2018, Scientific Reports.
[23] James J. Morrow,et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence , 2017, Nature Medicine.
[24] S. Pileri,et al. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 , 2017, Oncotarget.
[25] Michael Pryszlak,et al. Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics , 2017, Front. Oncol..
[26] J. Crowley,et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[27] Michael C. Ostrowski,et al. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein , 2017, Genes & development.
[28] D. Frishman,et al. Genome‐wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma , 2017, International journal of cancer.
[29] Anang A. Shelat,et al. Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.
[30] Lin F. Yang,et al. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells , 2017, Front. Immunol..
[31] L. Wagner,et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults , 2017, Cancer.
[32] D. Hawkins,et al. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] X. Zang,et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.
[34] I. Weissman,et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Munster,et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] J. Wolchok,et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[37] I. Weissman,et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential , 2015, PloS one.
[38] Q. Bi,et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models , 2015, Oncotarget.
[39] Hao Liu,et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[41] P. Meltzer,et al. Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma , 2014, Clinical Cancer Research.
[42] G. Nielsen,et al. Programmed Cell Death Ligand 1 Expression in Osteosarcoma , 2014, Cancer Immunology Research.
[43] Li Ding,et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.
[44] Jennifer B Dennison,et al. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.
[45] S. Keir,et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[46] David M. Thomas,et al. Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells , 2013, Sarcoma.
[47] Carl R Walkley,et al. Genetically engineered mouse models and human osteosarcoma , 2012, Clinical Sarcoma Research.
[48] L. Trani,et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] J. Khan,et al. Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. , 2012, Cancer research.
[50] P. Casali,et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] M. Rosemann,et al. Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma , 2010, Clinical Cancer Research.
[52] P. Meltzer,et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression , 2009, BMC Genomics.
[53] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[54] M. Paoloni,et al. Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.
[55] M. Lotze,et al. Pediatric Cancers Are Infiltrated Predominantly by Macrophages and Contain a Paucity of Dendritic Cells: a Major Nosologic Difference with Adult Tumors , 2006, Clinical Cancer Research.
[56] A. Jeltsch,et al. Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy , 2004, Cancer biology & therapy.
[57] Shishir Shah,et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma , 2004, BMC Cancer.
[58] L. Ngo,et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[59] P. Sorensen,et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas , 2003, Genes, chromosomes & cancer.
[60] C. Lagenaur,et al. Role of CD47 as a marker of self on red blood cells. , 2000, Science.
[61] M. Mcguire,et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. , 1997, Cancer genetics and cytogenetics.
[62] P. Casali,et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. , 2015, The Lancet. Oncology.
[63] W. Kisseberth,et al. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology. , 2014, ILAR journal.
[64] S. Withrow,et al. Cross talk from pets to people: translational osteosarcoma treatments. , 2010, ILAR journal.
[65] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] H. Koeffler,et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. , 1996, Journal of cancer research and clinical oncology.